Isotretinoin Pregnancy Warnings
Use is contraindicated.
AU TGA pregnancy category: X
US FDA pregnancy category: X
Comments:
-Female patients of reproductive potential should be tested for pregnancy before receiving a prescription for this drug.
-Any suspected fetal exposure during or 1 month after isotretinoin therapy must be reported at once to the FDA via the MedWatch number 1-800-FDA-1088 and also to the iPLEDGE pregnancy registry at 1-866-495-0654 or via the Internet (www.ipledgeprogram.com), and patients should be referred to a healthcare provider specialized or experienced in teratology.
-Effective contraception (at least 2 reliable forms) is required during therapy and for 1 month after the last dose; local protocol should be consulted regarding contraception timing.
Severe birth defects have occurred after exposure to this drug in any dose and over any duration, even for short periods of time. There are no accurate means to determine whether an exposed fetus is affected.
AU TGA pregnancy category X: Drugs which have such a high risk of causing permanent damage to the fetus that they should not be used in pregnancy or when there is a possibility of pregnancy.
US FDA pregnancy category X: Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.
See references
